a r t i c l e s
Epithelial and endothelial cell plasticity is crucial for embryonic development and disease progression 1 . Transformation of epithelial cells into mesenchymal cells (epithelial-to-mesenchymal transition, EMT) regulates gastrulation, neural crest and somite dissociation, craniofacial development, wound healing, organ fibrosis and tumor metastasis [2] [3] [4] [5] . Endothelial-to-mesenchymal transition (EndMT) is crucial for endocardial cushion formation [6] [7] [8] [9] [10] [11] , and recent studies show that EndMT in the tumor microenvironment generates carcinomaassociated fibroblasts 12 and may be essential for cancer progression 1 . Many fibroblasts formed during cardiac 13 and renal [14] [15] [16] fibrosis are of endothelial origin. EndMT is also implicated in atherosclerosis 17 , pulmonary hypertension 18 and wound healing 19 . However, whether mature endothelial cells can be induced to differentiate into a variety of cell fates is unknown.
Individuals with fibrodysplasia ossificans progressiva, a disease in which acute inflammation causes heterotopic ossification in soft tissues and formation of an ectopic skeleton 20 , carry a heterozygous activating mutation in the gene encoding ALK2, resulting in the substitution of a histidine for an arginine residue at amino acid 206 (R206H) (refs. 21-23) . Heterotopic ossification in FOP lesions begins with a mesenchymal condensation, followed by chondrogenesis and endochondral ossification 20 . The source of heterotopic cartilage and bone in FOP lesions is unknown.
On the basis of previous work indicating the importance of EndMT in human disease, we investigated whether FOP lesions could be derived from EndMT.
RESULTS

Endothelial origin of heterotopic cartilage and bone
To determine whether formation of heterotopic bone and cartilage in subjects with FOP could be caused by EndMT, we performed immunohistochemistry on lesional tissue from subjects with FOP using antibodies specific for the endothelial markers TIE2 and von Willebrand factor (vWF), for the osteoblast marker osteocalcin and for the chondrocyte marker SOX9. Cells in chondrogenic lesions showed coexpression of TIE2 and vWF with SOX9, whereas osteogenic lesions showed strong coexpression of TIE2 and vWF with osteocalcin in cells lining the calcified tissue (Fig. 1a) . Normal human bone and cartilage from the hip joint showed no evidence of TIE2-or vWF-positive chondrocytes or osteoblasts ( Fig. 1a and Supplementary Fig. 1a,b) . In a mouse model of heterotopic ossification induced by a transgene encoding constitutively active ALK2 (caALK2) (Fig. 1b) with amino acid change Q207D, immunohistochemistry of chondrogenic and osteogenic lesions showed Tie2-and vWF-positive chondrocytes and osteoblasts, as indicated by co-staining for these two proteins with Sox9 or with osteocalcin, respectively, suggesting that they arise from endothelial cells. For comparison, bone and cartilage from the knee joints of wild-type mice showed no evidence of Tie2-or vWF-positive chondrocytes or osteoblasts ( Fig. 1a and Supplementary Fig. 1c,d) .
To confirm the endothelial origin of heterotopic cartilage and bone, we used IRG reporter mice, which express EGFP in a Credependent manner, crossed with mice carrying a Tie2-Cre transgene, which express Cre under the control of the endothelial-specific Tie2 promoter, for cell lineage tracing. In the offspring, EGFP is expressed in cells of Tie2-positive lineage. We induced the formation of heterotopic cartilage and bone in these mice by injecting the ALK2-activating ligand BMP4 intramuscularly. Most of the chondrocytes and osteoblasts in these lesions, as visualized by staining with antibodies specific for Sox9 and osteocalcin, were EGFP positive. Furthermore, these EGFP-positive cells showed coexpression with the endothelial markers vWF, Tie1 and vascular endothelial cadherin (VE-cadherin) (Fig. 1c) .
Mutation in ALK2 causes endothelial-mesenchymal transition Infection of human umbilical vein endothelial cells (HUVECs) and human cutaneous microvascular endothelial cells (HCMECs) with adenoviral constructs encoding wild-type or R206H ALK2 resulted in greatly increased protein amounts of ALK2 compared to the empty vector control (Fig. 2a) . In cells expressing R206H ALK2, phosphorylation of ALK2 was readily detected by immunoblotting, whereas this was not the case in cells expressing wild type ALK2 or in the control cells (Fig. 2b) . R206H ALK2 expression caused a change in endothelial cell shape to a mesenchymal morphology and induced coexpression of the mesenchymal marker fibroblast-specific protein-1 (FSP-1) and the endothelial marker TIE2 by flow cytometry (Fig. 2c) .
Immunoblotting showed that expression of R206H ALK2 reduced protein amounts of the endothelial markers VE-cadherin, CD31 and vWF and increased expression of the mesenchymal markers FSP-1, α-smooth muscle actin (α-SMA) and N-cadherin. TIE2 expression did not change (Fig. 2d) . Increased protein expression of the EndMTassociated transcription factors 24 Snail, Slug, zinc finger E-boxbinding homeobox-1 (ZEB-1), Smad-interacting protein-1 (SIP-1), lymphoid enhancer-binding factor-1 (LEF-1) and Twist in cells expressing R206H ALK2 was confirmed by ELISA ( Supplementary  Fig. 2a ). Taken together, these results indicate that expression of constitutively active ALK2 induces EndMT.
Heterotopic ossification begins with mesenchymal condensation before chondrogenesis 20 . Our Tie2-Cre reporter mice showed EGFPpositive mesenchymal cells (co-stained with FSP-1-specific antibodies) in early lesions of BMP4-induced heterotopic ossification. These mesenchymal cells also expressed the endothelial markers vWF, Tie1 and VE-cadherin (Fig. 2e) . These data suggest an endothelial origin to the mesenchymal cells that give rise to chondrocytes and osteoblasts in heterotopic cartilage and bone.
EndMT induces a stem cell-like phenotype To determine whether endothelial cells expressing R206H ALK2 acquire a stem cell-like phenotype, we performed flow cytometry of cells with antibodies specific for the endothelial marker TIE2 and the mesenchymal stem cell (MSC) marker STRO-1. R206H ALK2-expressing cells showed coexpression of the two proteins by flow cytometry, whereas STRO-1 expression was not observed in cells expressing wild-type ALK2 or in control cells (Fig. 3a) . By immunoblotting, R206H ALK2-expressing cells also showed expression of the stem cell marker proteins 25 STRO-1, CD10, CD44, CD71, CD90 and CD117 (Fig. 3b) . Bone marrow-derived MSCs also showed expression of these proteins, whereas adult human corneal fibroblasts did not (Fig. 3b) . In addition, when we stained R206H ALK2-expressing cells with antibodies specific for the His-tagged R206H ALK2 protein and separated positively-and negatively-stained cells by FACS, only the positively-stained cell population expressed mesenchymal (FSP-1) and stem cell (STRO-1, CD44 and CD90) protein markers, as determined by immunoblotting ( Supplementary Fig. 3 ).
Because MSCs are multipotent, we next assessed the differentiation capabilities of endothelial cells that undergo EndMT. We exposed endothelial cells to the adenoviral expression constructs for 48 h and then grew the cells in osteogenic, chondrogenic or adipogenic culture media. Immunoblotting with antibodies specific for osteoblast (osterix), chondrocyte (SOX9) and adipocyte (peroxisome proliferatoractivated receptor-γ2 (PPAR-γ2)) markers showed induction of these proteins only in R206H ALK2 expressing cells when the cells were grown in the appropriate differentiation medium (Fig. 3c) . In addition, only R206H ALK2-expressing cells showed positive staining for alkaline phosphatase and a high degree of matrix calcification, as indicated by alizarin red staining, after growth in osteogenic medium for 7 and 21 d, respectively; positive staining with the cartilage proteoglycan stain alcian blue after growth in chondrogenic medium for 14 d; and oil red O staining after growth in adipogenic medium (Fig. 3d) . The differentiation potential of endothelial-derived mesenchymal stem-like cells was similar to that of bone marrowderived MSCs, whereas human corneal fibroblasts did not show differentiation activity under the same conditions ( Supplementary  Fig. 4 ). We found that induction of endothelial cell differentiation into each of the osteogenic, chondrogenic or adipogenic lineages by R206H ALK2 expression could also occur when polylactic acid sponges containing HUVECs or HCMECs, which had been pretreated with the adenoviral constructs, were implanted into immunodeficient nude mice, followed by local injection of the appropriate differentiation medium every 72 h for 6 weeks (Fig. 3e) .
Ligand-specific induction of EndMT TGF-β2 and BMP4 are ligands known to activate ALK2 (refs. 26,27) . We therefore examined receptor phosphorylation in endothelial cells treated with these factors. Immunoprecipitation with antibodies specific for ALK2 followed by immunoblotting with phosphotyrosinespecific antibodies indicated that treatment with TGF-β2 or BMP4 for 15 min induced receptor phosphorylation, but treatment with the vehicle control did not (Fig. 4a) . HUVECs and HCMECs treated with recombinant TGF-β2 or BMP4 for 48 h showed a distinct change from a cobblestone-like endothelial cell morphology to a fibroblastlike morphology (Fig. 4b) . When cells were co-stained with antibodies specific for the endothelial marker TIE2 and the mesenchymal marker FSP-1 and analyzed by flow cytometry, vehicle-treated cells were positive for TIE2 but showed no staining for FSP-1, whereas TGF-β2 or BMP4 treated cells showed staining for both (Fig. 4b) . Immunoblotting showed that VE-cadherin, CD31 and vWF amounts decreased in cells treated with TGF-β2 or BMP4, whereas FSP-1, α-SMA and N-cadherin amounts increased and TIE2 expression remained unchanged (Fig. 4c) . As assessed by ELISA, expression of the EndMT-associated transcription factors Snail, Slug, ZEB-1, SIP-1, LEF-1 and Twist was much higher in cells treated with TGF-β2 or BMP4 than in control cells (Supplementary Fig. 2b) .
We next stained ligand-treated endothelial cells with antibodies specific for the endothelial marker TIE2 and the MSC marker STRO-1. Cells treated with TGF-β2 or BMP4 showed concurrent expression of both markers by flow cytometry, whereas vehicle-treated cells showed no expression of STRO-1 (Fig. 5a) . Immunoblotting showed that STRO-1 and other MSC markers (CD10, CD44, CD71, CD90 and CD117) were not expressed in vehicle-treated cells but were strongly expressed in cells treated with TGF-β2 or BMP4 (Fig. 5b) . These results indicate that ligand-induced ALK2 activation induces EndMT and acquisition of a stem cell-like phenotype.
To assess effects on cell differentiation, we treated endothelial cells with vehicle, TGF-β2 or BMP4 for 48 h, followed by growth in osteogenic, chondrogenic or adipogenic culture medium. Immunoblotting showed that cells treated with TGF-β2 or BMP4 and grown in osteogenic medium for 7 d, chondrogenic medium for 14 d or adipogenic medium for 7 d showed increases in protein expression of the osteoblast marker osterix, the chondrocyte marker SOX9 or the adipocyte marker PPAR-γ2, respectively, whereas vehicle-treated cells did not express these markers (Fig. 5c) . Similarly, cells treated with TGF-β2 or BMP4 and grown in osteogenic medium for 7 d or 21 d stained for alkaline phosphatase or alizarin red, respectively; and these cells grown in chondrogenic medium for 14 d or in adipogenic medium for 7 d stained for alcian blue and oil red O, respectively (Fig. 5d) . We confirmed multipotency in vivo by implanting polylactic acid sponges containing endothelial cells that had been pretreated with vehicle, TGF-β2 or BMP4 into immunodeficient nude mice, followed by local injection of differentiation medium every 72 h for 6 weeks. Only implants with cells pretreated with TGF-β2 or BMP4 showed formation of bone, cartilage or fat (Fig. 5e) . Next, we prelabeled HUVECs and HCMECs with fluorescent quantum dots before treatment and implantation. The labeled cells treated with TGF-β2 or BMP4 showed expression of osteocalcin, SOX9 or adiponectin when exposed in vivo to osteogenic, chondrogenic or adipogenic medium, respectively, whereas vehicle-treated cells did not (Supplementary Fig. 5 ).
These cell-tracing experiments confirm endothelial cell differentiation to osteoblasts, chondrocytes and adipocytes.
Receptor specificity in EndMT
We next tested whether ALK2 is necessary for acquisition of the multipotent stem cell-like phenotype induced by TGF-β2 or BMP4 treatment. Endothelial cells were transfected for 24 h with an siRNA duplex specific for ALK2. A scrambled nonspecific siRNA duplex was used as a negative control. Immunoblotting of cell lysates showed complete inhibition of ALK2 expression by the ALK2-specific siRNA (Fig. 6a) . Transfected cells were subsequently treated with vehicle, TGF-β2 or BMP4 for 48 h, followed by immunoblotting for the mesenchymal and stem cell markers FSP-1 and STRO-1. TGF-β2-or BMP4-treated cells transfected with control siRNA had much higher expression of FSP-1 and STRO-1 than did vehicle-treated cells, whereas ALK2-specific siRNA treatment blocked these increases (Fig. 6b) . We confirmed these results by flow cytometry using antibodies specific for TIE2 and FSP-1. TGF-β2 or BMP4 induced FSP-1 expression in most cells that had been transfected with control siRNA but only in very few cells that had been transfected with ALK2-specific siRNA; vehicle-treated cells that had been transfected with either control or ALK2-specific siRNA showed no positive staining for FSP-1 (Fig. 6c) . Treatment with the ALK2 inhibitor dorsomorphin also blocked EndMT (Supplementary Fig. 6a ). TGF-β2-or BMP4-treated cells that had been transfected with control siRNA stained positively for alkaline phosphatase after culture in osteogenic medium for 7 d, whereas vehicle-treated cultures and cells transfected with ALK2-specific siRNA showed no staining for alkaline phosphatase (Fig. 6d) . We found similar results for alizarin red staining after 21 d of incubation in osteogenic medium, alcian blue staining after 14 d of incubation in chondrogenic medium and oil red O staining after 7 d of incubation in adipogenic medium (Fig. 6d) .
Whereas some ALK2-activating ligands such as TGF-β2 and BMP4 stimulate EndMT, the activating ligand BMP7 inhibits EndMT 13 . We confirmed this by immunoblotting lysates of HUVECs treated with TGF-β2 and BMP7 and found no changes in expression of endothelial and mesenchymal markers (Supplementary Fig. 6b) . Vascular endothelial growth factor (VEGF) also inhibited TGF-β2-induced EndMT (Supplementary Fig. 6b) . To examine whether different ALK2 ligands had different effects on downstream signaling, we assessed the degree of phosphorylation of Smad2 and Smad5, proteins activated by TGF-β or BMP signaling. Immunoblotting showed that 1 h of treatment with TGF-β2 or BMP4 promoted phosphorylation of both Smad2 and Smad5, whereas 1 h of treatment with BMP7 stimulated phosphorylation of only Smad5 (Supplementary Fig. 7a ). Because ALK2 has been found to physically interact with Smad5 but not with Smad2 (ref. 26) , we tested the possibility that ALK2 induces Smad2 phosphorylation indirectly, through an interaction with ALK5 (TGF-β receptor I), which is known to induce phosphorylation of Smad2 (ref.
2). Immunoblotting of lysates immunoprecipitated with ALK2-specific antibodies showed the presence of ALK5 in precipitates from cells treated with TGF-β2 or BMP4, but not in precipitates from vehicle-or BMP7-treated cells ( Supplementary  Fig. 7b ). We next tested this signaling specificity for R206H ALK2. As in TGF-β2-or BMP4-treated cells, R206H ALK2-expressing cells, but not wild type ALK2-expressing or control cells, contained phosphorylated Smad2 and Smad5, and an interaction between ALK2 and ALK5 could be detected only in the R206H ALK2-expressing cells (Supplementary Fig. 7c,d) .
To further define the role of ALK receptors in EndMT, we performed expression knockdown studies with siRNAs targeting each of the ALK receptors. The EndMT-associated decrease in VE-cadherin and increase in CD44 expression induced by TGF-β2 or BMP4 were inhibited by ALK2-specific siRNA or ALK5-specific siRNA, whereas knockdown of ALK1, ALK3, ALK4, ALK6 or ALK7 expression had no effect (Supplementary Fig. 8 ). These data suggest that both ALK2 and ALK5 are necessary for EndMT.
We found that expression of the endothelial markers vWF, TIE1 and VE-cadherin is reduced yet still detectable throughout EndMT (Figs. 2d  and 4c) . TIE2 levels remained constant through 48 h of treatment with TGF-β2 or BMP4, but a small decrease was observed after 96 h of treatment (Supplementary Fig. 9a) . Therefore, we believe that all of these markers can be used to detect endothelial-derived cells that have differentiated into other cell types via the endothelial-to-stemlike cell mechanism. To confirm that osteoblasts, chondrocytes and adipocytes derived from endothelial cells express these markers, we immunoblotted lysates collected from HCMEC cultures treated with vehicle, TGF-β2 or BMP4 for 48 h and grown in osteogenic medium for 7 d, chondrogenic medium for 14 d or adipogenic medium for 7 d. Osteogenic medium induced expression of the osteoblast marker osteocalcin, chondrogenic medium increased expression of the chondrocyte marker SOX9 and adipogenic medium induced expression of the adipocyte marker PPAR-γ2 (Supplementary Fig. 9b) . Bone marrow-derived MSCs grown in the same differentiation media showed positive expression of these proteins as well, but cells grown in conventional growth medium did not ( Supplementary  Fig. 9b) . Notably, MSCs and osteoblasts, chondrocytes and adipocytes derived from MSCs showed no detectable expression of the endothelial markers TIE2, vWF, VE-cadherin or TIE1. Primary human osteoblasts, chondrocytes and adipocytes also showed no expression of these markers (Supplementary Fig. 9b ).
In addition, whereas a homogeneous population of hematopoietic stem cells expresses TIE2 and low levels of TIE1, they did not express the endothelial-specific markers vWF or VE-cadherin (Supplementary Fig. 10 ).
DISCUSSION
Our findings provide new insights into the mechanism and potential roles of EndMT. First, the data show that EndMT results in the generation of mesenchymal stem-like cells that can differentiate into multiple cell lineages. The current view is that EndMT produces fibroblastic cells that participate in specific developmental processes, in cancer progression and in organ fibrosis 1 , but evidence for an endothelial-derived stem-like cell broadens the scope for the role of EndMT in normal development, tissue repair and disease. For example, the observation that chondrocytes and osteoblasts at sites of bone fracture repair stain positive with antibodies specific for endothelial markers 28 suggests that EndMT may contribute to the physiological process of fracture repair. Studies of the sources of chondrocytes and osteoblasts in fracture repair and the related process of distraction osteogenesis 29 should be of interest. Second, our data indicate that activation of ALK2 is necessary and sufficient for EndMT to occur in cells such as HUVECs and HCMECs under the in vitro conditions used in this study. The finding that a major fraction of the chondrocytes and osteoblasts in ectopic ossifying lesions of mice and humans with an activating mutation in ALK2 are likely to be derived from endothelial cells indicates that the process can occur also in vivo. Our data show that TGF-β2 and BMP4 are stimulators of EndMT and confirm that BMP7 and VEGF are inhibitors of EndMT 13, 30, 31 . The negative effect of VEGF on ALK2-mediated EndMT may explain why endochondral and not direct (membranous) bone formation occurs in the lesions of people with FOP 20 . Chondrogenesis occurs in an antiangiogenic, hypoxic environment 32 ; this may be an environment that favors ALK2-mediated EndMT and chondrogenesis at lesion sites, as hypoxia occurs as a result of inflammation 33 . In contrast, bone formation requires angiogenesis, and osteoblasts produce VEGF 34 . This implies that a lack of VEGF may be necessary for EndMT and chondrogenesis in FOP lesions. Factors that cause endothelialderived cells to convert to chondrocytes in FOP are currently unknown. However, it is likely that inflammatory cytokines are crucial, as the ectopic ossifying lesions are triggered by inflammation 20 .
Last, our data indicate that FOP, in which the hallmark is pathological bone formation, is a vascular disease based on conversion of endothelial cells into mesenchymal stem-like cells. Accumulation of mesenchymal cells is an early step in the formation of FOP lesions, and this was previously thought to be a result of fibroblast proliferation 23 . Our data raise the possibility that mesenchymal condensation before chondrogenesis is the result of EndMT to stem-like cells that condense and differentiate into chondrocytes by a process that mimics early steps in skeletal development 32 . Our data show that the majority of the chondrocytes and osteoblasts found in human FOP lesions, as well as in the lesions of mouse models of FOP, express endothelial markers. We used Tie2-Cre reporter mice for endothelial cell lineage tracing, and although we showed that Tie2 can be expressed in hematopoietic cells, the EGFP-positive mesenchymal cells, chondrocytes and osteoblasts in the lesions stained positive for the endothelial-specific markers VE-cadherin and vWF, which are not found in hematopoietic cells. Furthermore, previous studies have found no evidence of hematopoietic origin of heterotopic cartilage and bone 35 . These findings suggest that the cells marked by the Tie2-Cre reporter are unlikely to be derived from hematopoietic cells. The origin of the relatively small fraction of cells in FOP lesions that do not express endothelial markers is unknown, but it is possible that these cells arise from mesenchymal stem cells recruited from the bone marrow or surrounding tissues.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
